First-in-class radio-theranostic utilizes novel antibody developed at UT MD Anderson
Study details the development of a novel antibody that targets a specific type of B7-H3, a protein overexpressed in many cancers
This antibody technology was used to create BetaBart, an investigational new radio-theranostic drug currently being evaluated in a Phase I/II clinical trial
If successful, this approach could bring the benefits of radio-theranostics to several cancer...
